<DOC>
	<DOCNO>NCT00773747</DOCNO>
	<brief_summary>Study efficacy safety bortezomib administer combination vorinostat patient relapse refractory multiple myeloma . Histone deacetylases ( HDAC ) facilitate gene transcription modulate uncoiling chromatin . HDAC function dysregulated hematologic solid malignancy , dysregulation may result over-expression oncogene . Thus , inhibition HDACs may result anti-cancer effect . HDAC inhibitor , like vorinostat , represent new class antitumor agent ability induce antiproliferative effect include cyto-differentiation , cell cycle growth arrest apoptosis various cancer cell line . Several study investigate vitro antimyeloma activity vorinostat combination bortezomib demonstrate vorinostat may act synergistically bortezomib modulate tumor cell growth . Mitsiades et al show vorinostat enhances sensitivity bortezomib . Pei et al find exposure human multiple myeloma cell line &amp; patient-derived multiple myeloma cell bortezomib vorinostat result synergistic interaction result : ( 1 ) Interruption NF-kB &amp; relate signaling pathway ( JNK , XIAP , Mcl-1 , etc . ) ( 2 ) Inhibition Hsp90 ( 3 ) Induction ER stress signal ( 4 ) acetylation Dynein/disruption aggresome function/formation , salvage ubiquitinated protein . In addition mark increase mitochondrial injury , caspase activation , apoptosis also observe . Bortezomib indicate treatment patient multiple myeloma . Two Phase I dose-ranging study regimen combine vorinostat bortezomib among patient relapse well asend-stage , refractory multiple myeloma conduct . These study enrol total 57 patient . In study , administration vorinostat standard dos bortezomib result response 20/45 ( 44 % ) evaluable patient ( Weber et al 2007 , Badros et al 2007 ) . The purpose present study definitively evaluate clinical activity vorinostat combination bortezomib inpatient multiple myeloma .</brief_summary>
	<brief_title>Study Vorinostat ( MK-0683 ) HDAC Inhibitor , Placebo Combination With Bortezomib Patients With Multiple Myeloma ( MK-0683-088 AMN )</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<mesh_term>Analgesics</mesh_term>
	<mesh_term>Peripheral Nervous System Agents</mesh_term>
	<mesh_term>Anti-Inflammatory Agents , Non-Steroidal</mesh_term>
	<mesh_term>Molecular Mechanisms Pharmacological Action</mesh_term>
	<criteria>Inclusion criterion Participant establish diagnosis multiple myeloma base myeloma diagnostic criterion . Participant receive least 1 3 prior antimyeloma regimen progressive disease recent treatment regimen . Participant must adequate organ function . Exclusion criterion : Participant prior allogeneic bone marrow transplant plan undergo type bone marrow transplantation within 4 week initiation study therapy . Participant known hypersensitivity component bortezomib vorinostat . Participant active Hepatitis B C , plasma cell leukemia , human immunodeficiency virus ( HIV ) positive . Participant prior treatment vorinostat histone deacetylase ( HDAC ) inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Neoplasms , Plasma Cell</keyword>
	<keyword>Neoplasms Histologic Type</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Hemostatic Disorders</keyword>
	<keyword>Vascular Diseases</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Paraproteinemias</keyword>
	<keyword>Blood Protein Disorders</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Hemorrhagic Disorders</keyword>
	<keyword>Lymphoproliferative Disorders</keyword>
	<keyword>Immunoproliferative Disorders</keyword>
	<keyword>Immune System Diseases</keyword>
	<keyword>Vorinostat</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Anti-Inflammatory Agents , Non-Steroidal</keyword>
	<keyword>Analgesics , Non-Narcotic</keyword>
	<keyword>Analgesics</keyword>
	<keyword>Sensory System Agents</keyword>
	<keyword>Peripheral Nervous System Agents</keyword>
	<keyword>Physiological Effects Drugs</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Anti-Inflammatory Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Antirheumatic Agents</keyword>
	<keyword>Antineoplastic Agents</keyword>
	<keyword>Enzyme Inhibitors</keyword>
	<keyword>Molecular Mechanisms Pharmacological Action</keyword>
	<keyword>Anticarcinogenic Agents</keyword>
</DOC>